Certolizumab pegol

Certolizumab pegol, sold under the brand name Cimzia, is a biopharmaceutical medication for the treatment of Crohn's disease,[4][5] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.

[6][7][2] It is on the World Health Organization's List of Essential Medicines.

[8] Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha.

More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.

Three certolizumab molecules (blue) binding a homotrimer of TNF-alpha (tan). Certolizumab can block TNF in both its soluble form (freely circulating in the bloodstream) and its transmembrane form (bound to the membrane of a cell). From PDB : 5WUX ​. [ 12 ]